'Show' and 'Shadow' Heparin Facilities Targeted in Pair of FDA Warning Letters

FDA issued heparin-related warning letters last month to two Chinese API suppliers - one for posing as a heparin API supplier, and the other for supplying adulterated heparin to the U.S. in violation of cGMP requirements

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet